ECVT: Q3 Adjusted EBITDA rose 6.4%; FY 2026 guidance midpoint increased by $9M

What happened

ECVT reported that third-quarter sales rose 50.6% and adjusted EBITDA, a measure of operating earnings before certain costs, increased 6.4%. The company attributed the gains to higher sales volume, pricing and Calabrian contribution, and raised the midpoint of its fiscal 2026 adjusted EBITDA guidance by $9M.

Confirmed

Global impact / market context

The results point to stronger sales and earnings, while the higher guidance midpoint signals a better expected earnings outlook for fiscal 2026. Higher volume and pricing can increase revenue, and Calabrian’s contribution added to the reported gains, but the summary gives no detail on costs or cash available.

Analyst inference

The reported 50.6% sales increase was much larger than the 6.4% adjusted EBITDA gain, so sales growth did not translate into equally strong earnings growth in the quarter. Without figures for costs or the guidance range, investors cannot tell what drove that gap or how broad the outlook change was.

Analyst inference

What to watch

1. Look for the next company update to show whether sales volume and pricing continue to support revenue growth and whether adjusted EBITDA rises at a similar pace. Analyst inference
2. Check for details on Calabrian’s contribution and any related costs, since the summary identifies it as a factor but does not quantify its effect. Analyst inference
3. Compare future fiscal 2026 adjusted EBITDA guidance with the raised midpoint to see whether the company maintains or changes its earnings outlook. Analyst inference

Evidence

• Original source link unavailable